Cytochroma
PrivateLast Round
Accelerator
Sep 15, 2025
Total Funding Raised
$1.64M
Company Overview
Cytochroma operates in Healthcare & Life Sciences and is based in Edinburgh. Its latest recorded funding round was an Accelerator round in September 2025.
Cytochroma is a biotechnology company that provides genetically diverse, iPSC-derived cell models and screening services to predict drug safety and efficacy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cytochroma Comparables
Compare Cytochroma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Xellar Biosystems | 84% | |
| Curi Bio | 81% | |
| Hesperos Inc. | 79% |
For institutional investors. Book with your work email.
Cytochroma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Sep 15, 2025 | ||||
| Early Funding | Oct 17, 2024 | ||||
| Seed | Dec 16, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cytochroma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investing Women Angels | Seed, Early Funding |
| Angel Academe | Seed |
| Morgan Stanley Inclusive & Sustainable Ventures | Accelerator |
| Cambridge Capital Group | Seed |
| Innovate UK | Seed |
| Scottish Investment Bank (Scottish Enterprise) | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2025
$340K round led by Morgan Stanley Inclusive & Sustainable Ventures
- Oct 17, 2024
Received investment from Investing Women Angels.
For institutional investors. Book with your work email.
Cytochroma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cytochroma's valuation, stock price, and market status.
Is Cytochroma a public or private company?
Cytochroma is a private company.
What is the current stock price of Cytochroma?
Cytochroma is a private company, so its shares have no public market price. Caplight tracks Cytochroma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cytochroma worth (valuation)?
Valuation information for Cytochroma is not publicly available.
Can I buy Cytochroma stock?
Cytochroma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cytochroma's last funding round?
Cytochroma's most recent funding round was Accelerator on September 15, 2025.
Who are the main investors in Cytochroma?
Key investors in Cytochroma include Angel Academe, Morgan Stanley Inclusive & Sustainable Ventures.
Will Cytochroma IPO soon?
No public IPO plans have been announced for Cytochroma.
How can I track Cytochroma secondary market activity?
Caplight tracks bids, offers, and trades in Cytochroma's shares on secondary markets.